Navigation Links
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/5/2008

Interim Phase 1 Data Presented at International Conference on Malignant

Lymphomas Shows Dose Dependent Single Agent Activity

BETHESDA, Md., June 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland. The new data(1) with the CD19-specific BiTE antibody show that all seven patients in the highest dose cohort tested so far (0.06 mg/m2/day) achieved complete or partial responses.

In the study, relapsed, incurable non-Hodgkin's lymphoma (NHL) patients who previously failed a median of three (and up to 12) conventional therapies were treated with increasing doses of blinatumomab (MT103/MEDI-538) for four to eight weeks. Dose-dependent clinical activity was observed. At the recently completed cohort of 0.06 mg/m2 per day, seven out of seven patients showed either complete or partial responses. Remissions in this and the previous dose cohort continue in all patients, with the longest remission ongoing for more than one year. Most frequent side effects observed so far were lymphopenia, pyrexia, and leukopenia. Less common adverse events included transient neutropenia and thrombocytopenia, transient increase of liver enzymes, and central nervous system events, all of which were fully reversible.

"The high response rate and apparently durable remissions in this heavily pre-treated patient population support blinatumomab as a single agent therapy with the potential for accelerated development," said Micromet's Senior Vice President and Chief Medical Officer, Dr. Carsten Reinhardt.

"ICML brings together thousands of the world's leading specialists and researchers to present the latest adva
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
2. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
5. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 ... collapse of one or more vertebral bodies, resulting ... a degenerative bone disease, is a leading cause ... multiple myeloma, metastatic spinal tumors, and traumatic injuries ... vertebroplasty and kyphoplasty to rectify the condition. Both ...
(Date:9/2/2015)... , Sept. 2, 2015 Advanced Wound ... Summary Advanced dressings have steadily replaced traditional ... a variety of wound indications, such as trauma ... infection control, and physical protection become increasingly critical ... role in standard therapy. This report focuses ...
(Date:9/2/2015)... Advanced Wound Dressings - 5EU Analysis ... have steadily replaced traditional bandages and gauze materials ... indications, such as trauma wounds, burns, and chronic ... protection become increasingly critical in wound healing, advanced ... This report focuses on nine market categories ...
Breaking Medicine Technology:Global Balloon Kyphoplasty Market 2015-2019 2Advanced Wound Dressings - SA Analysis and Market Forecasts 2Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2
... 10, 2011 On Friday, June 10, 2011 at ... has been assigned to Joseph F. Finn, Jr., C.P.A. ... will be liquidated for the benefit of NMT Medical ... advanced medical technology company that designed, developed, manufactured and ...
... Company (Nasdaq: PRGO ; TASE) today announced that ... fluticasone lotion brought by Nycomed US Inc. by taking a ... settlement, Perrigo can launch a generic version of Cutivate® lotion ... Cutivate® (fluticasone) lotion is indicated for the ...
Cached Medicine Technology:NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve O'Clock Noon 2Perrigo Announces Settlement of Cutivate Lotion Litigation 2
(Date:9/2/2015)... ... September 02, 2015 , ... On ... Officers Association of America (MOAA) and Wounded Warrior Project® (WWP), will be ... Own,” expert panelists will lead interactive discussions on the responsibilities and commitments ...
(Date:9/2/2015)... ... , ... Telehealth represents a growing trend among Blue Cross and Blue Shield ... more than 12 Blues plan clients. The September 2015 issue of The ... trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next year. ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... In “Failure ... by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong struggle ... the author acknowledged that she had always seen herself as someone who would lose ...
(Date:9/2/2015)... ... 02, 2015 , ... Splashtop Inc., the worldwide leader in ... mirroring and extending product line -- Splashtop Wired XDisplay . Complementing ... setting, the new Splashtop Wired XDisplay delivers enhanced performance and reliability for users ...
(Date:9/2/2015)... ... ... Good health and a good cause paired up at The Barclays this past ... to the New Jersey Golf Foundation through its Healthy Steps Challenge. After making ... BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to add more by ...
Breaking Medicine News(10 mins):Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3
... to warn Indonesians about bird flu will commence next week,. ... of 49 people in the country which ranks as ... to John Budd, head of communications with the United Nations ... several members of socio- religious groups will be involved in ...
... and vitamin D supplements is apparently of no use in ... //from the Women's Health Initiative study. Previous research had suggested ... risk. ,'We can't yet make a general recommendation ... each day as supplements,' said Dr. Rowan Chlebowski, the study's ...
... 200 elderly people in the Argyll and Bute Council area ... it has emerged//. Labour MSP Jackie Baillie said that the ... investigate. ,Argyll and Bute Council said it had ... that there were about 200 eligible people not receiving care, ...
... major Ranbaxy Laboratories Ltd today said its wholly owned ... //with Hyderabad-based Zenotech Laboratories Ltd to market generic cancer ... the agreement, Zenotech Labs would develop, submit for regulatory ... Ranbaxy would market these products as generic formulations in ...
... Togadiya, who underwent an angioplasty at a private hospital here, ... ,Togadiya was admitted to SAL hospital here yesterday, ... Bhupesh Shah carried out the angioplasty on Togadiya last night., ... of the leader is stable and he is expected to ...
... beer while watching the World Cup on television may be ... the game, says a new study. // ,Psychology ... are not confident of their sporting abilities are likely to ... ,The study, based on interviews with 31 London youths in ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: